Unoprostone
Unoprostone (INN), classified as a prostaglandin analogue, has garnered attention in ophthalmic pharmacology[1]. Its isopropyl ester derivative, unoprostone isopropyl, is marketed under the brand name "Rescula" in a 0.15% eye drop formulation. Its primary applications include the management and treatment of open-angle glaucoma and ocular hypertension[2].
Chemical Classification and Structure[edit | edit source]
Unoprostone is part of the prostaglandin family, which includes lipid compounds exhibiting a wide spectrum of physiological properties. These molecules, derived enzymatically from fatty acids, significantly impact several physiological and pathological processes[3].
Therapeutic Applications[edit | edit source]
Open-angle Glaucoma[edit | edit source]
Open-angle glaucoma, prevalent among glaucoma types, arises from the gradual blockage of the eye's drainage channels, leading to increased eye pressure. Unoprostone, by promoting the outflow of aqueous humor, assists in reducing this pressure, thus lowering the optic nerve damage risk[4].
Ocular Hypertension[edit | edit source]
In ocular hypertension, where there's increased intraocular pressure without evident optic nerve damage or vision loss, unoprostone offers therapeutic benefits by managing this elevated pressure[5].
Formulation and Administration[edit | edit source]
The commercialized derivative, unoprostone isopropyl, comes as "Rescula" eye drops with a 0.15% concentration. Typically, an ophthalmologist determines the administration frequency and dosage based on the disease's severity.
Side Effects and Precautions[edit | edit source]
Unoprostone, akin to its prostaglandin analogues, may trigger side effects. Common manifestations include ocular irritation, redness, and potential eyelash growth alterations[6]. It remains crucial for patients to maintain regular consultations with their ophthalmologist throughout the treatment.
See Also[edit | edit source]
References[edit | edit source]
- ↑ Hellberg, M. R., McLaughlin, M. A., Sharif, N. A., DeSantis, L., Dean, T. R., & Kyba, E. P. (2001). Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Survey of ophthalmology, 45, S205-S212.
- ↑ Sharif, N. A., & Wiernas, T. K. (2009). Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Investigative ophthalmology & visual science, 50(2), 712-724.
- ↑ Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, thrombosis, and vascular biology, 31(5), 986-1000.
- ↑ Netland, P. A. (2001). Reduction of intraocular pressure with prostaglandins and prostamides. Survey of ophthalmology, 45, S93-S98.
- ↑ Fechtner, R. D., & Realini, T. (2004). Fixed combinations of topical glaucoma medications. Current opinion in ophthalmology, 15(2), 132-135.
- ↑ Liu, J. H., & Sit, A. J. (2011). Mechanism of side effects of prostaglandin analogs. In Glaucoma (pp. 145-152). Kugler Publications.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
